Editorial

DOI: 10.4244/EIJ-E-24-00068

Direct oral anticoagulants for ventricular thrombus resolution: pilot trials show reassuring efficacy and safety compared to warfarin

Felicita Andreotti1,2, MD, PhD; Francesco Burzotta1,2, MD, PhD

Direct oral anticoagulants (DOACs) are easier to use than warfarin1. They are effective and safe in treating venous thromboembolism and in preventing strokes related to most forms of atrial fibrillation (AF)12. DOACs are also recommended for patients with AF and comorbid acute coronary syndromes or undergoing percutaneous coronary intervention (PCI)345. DOACs are contraindicated, however, in patients with thrombotic antiphospholipid syndrome, mechanical heart valves, and rheumatic heart disease, given their lower efficacy and safety compared to warfarin12. For AF associated with end-stage renal disease and – until recently – for left ventricular thrombus (LVT) resolution, the evidence from randomised controlled trials (RCTs) has been insufficient to formulate strong recommendations for or against DOACs2.

LVT after an acute myocardial infarction (MI) can cause devastating embolic strokes36. The incidence of post-infarct LVT has declined thanks to timely pharmacological and mechanical recanalisation that has drastically limited infarct size367. The mechanisms underlying post-infarct LVT formation follow Virchow’s triad and involve ventricular dysfunction and deformation (especially aneurysmatic), flow abnormalities, and prothrombotic/inflammatory reactions in...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 1
Jan 6, 2025
Volume 21 Number 1
View full issue


Key metrics

Suggested by Cory

Viewpoint

10.4244/EIJ-D-24-00943 Jul 21, 2025
Factor XI inhibition for ACS patients: premises and prospects
Lopes R and Fanaroff A
free

10.4244/EIJV16I2A18 Jun 12, 2020
Dropping P2Y12 inhibitors in patients with AF undergoing PCI? Not yet a SAFE bet
Lopes RD and Fanaroff A
free

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
Trending articles
318.3

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
116.85

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
108.3

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
91.6

Image – Interventional flashlight

10.4244/EIJ-D-22-00344 Aug 5, 2022
First dedicated transcatheter leaflet splitting device: the ShortCut device
Tchétché D et al
free
71.3

State-of-the-art

10.4244/EIJ-D-22-00627 Feb 6, 2023
Left atrial appendage occlusion
Holmes D et al
free
68.9

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
42.95

State-of-the-Art Review

10.4244/EIJ-D-21-00145 Sep 20, 2021
Robotics, imaging, and artificial intelligence in the catheterisation laboratory
Beyar R et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved